Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
Carbapenem-Resistant Enterobacteriaceae Infection
About this trial
This is an interventional treatment trial for Carbapenem-Resistant Enterobacteriaceae Infection focused on measuring carbapenem resistance, Enterobacteriaceae, CRISPR/Cas9
Eligibility Criteria
Inclusion Criteria: Subjects clinically suspected of infection caused by Enterobacterales Subjects with bloodstream infection by MBL-producing Enterobacterales Exclusion Criteria: Infections caused by viruses, fungi, atypical pathogens, and other non-Enterobacteriaceae bacteria subjects who are unwilling to enter the research group
Sites / Locations
- Mingju HaoRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
CAZ/AVI plus Aztreonam
Conventional treatment
CAZ-AVI was administered at the dose of 2.5 g every 8 hours and ATM at the dose of 2 g every 8 hours
Other active antibiotics were administered, including colistin, tigecycline, fosfomycin, meropenem.